Convatec Group PLC

AGM Information • May 7, 2021

National Storage Mechanism | Additional information

RNS Number : 9695X

ConvaTec Group PLC

07 May 2021

ConvaTec Group Plc

Results of Annual General Meeting

Reading, United Kingdom 7 May 2021 - Poll Result

ConvaTec Group Plc ("ConvaTec") held its annual general meeting today ("AGM"). The results of the poll held in relation to the resolutions proposed at the AGM are set out below:

		For (see note 2)		Against (see note 2)		Total Votes cast	% of ISC Voted	Number of Votes Withheld (see note 3)
Resolution		No of shares	%	No of shares	%
1	Receive Annual Report and Accounts	1,744,608,352	99.96	777,616	0.04	1,745,385,968	87.08%	1,480,001
2	Approve the Directors' Remuneration Report	1,698,130,077	97.23	48,413,492	2.77	1,746,543,569	87.14%	322,400
3	Declare Final Dividend	1,740,839,314	99.66	5,915,934	0.34	1,746,755,248	87.15%	110,721
4	Re-elect John McAdam as a director	1,726,805,777	98.88	19,520,971	1.12	1,746,326,748	87.13%	539,221
5	Re-elect Karim Bitar as a director	1,745,847,330	99.95	907,151	0.05	1,746,754,481	87.15%	111,488
6	Re-elect Frank Schulkes as a director	1,739,573,569	99.59	7,176,168	0.41	1,746,749,737	87.15%	116,232
7	Re-elect Margaret Ewing as a director	1,735,171,507	99.34	11,573,127	0.66	1,746,744,634	87.15%	121,335
8	Re-elect Brian May as a director	1,726,852,048	98.86	19,898,392	1.14	1,746,750,440	87.15%	115,529
9	Re-elect Rick Anderson as a director	1,732,922,453	99.21	13,822,181	0.79	1,746,744,634	87.15%	121,335
10	Re-elect Regina Benjamin as a director	1,733,824,898	99.26	12,925,036	0.74	1,746,749,934	87.15%	116,035
11	Re-elect Sten Scheibye as a director	1,745,567,146	99.93	1,187,335	0.07	1,746,754,481	87.15%	111,488
12	Elect Heather Mason as a director	1,744,886,278	99.89	1,863,459	0.11	1,746,749,737	87.15%	116,232
13	Elect Constantin Coussios as a director	1,744,393,943	99.87	2,356,497	0.13	1,746,750,440	87.15%	115,529
14	Re-appoint Deloitte LLP as auditor	1,746,633,262	99.99	118,345	0.01	1,746,751,607	87.15%	114,362
15	Authorise the directors to determine the remuneration of the Company's auditor	1,746,753,488	100.00	433	0.00	1,746,753,921	87.15%	112,048
16	Authorise political donations and political expenditure	1,721,717,493	98.58	24,812,022	1.42	1,746,529,515	87.14%	336,454
17	Authorise allotment of shares	1,623,589,106	92.97	122,709,426	7.03	1,746,298,532	87.13%	567,437
18	Disapply pre-emption rights*	1,736,680,253	99.45	9,522,182	0.55	1,746,202,435	87.12%	663,534
19	Disapply pre-emption rights in connection with an acquisition or specified capital investment*	1,691,979,685	96.87	54,580,936	3.13	1,746,560,621	87.14%	305,348
20	Authorise purchase of own shares*	1,741,411,621	99.75	4,350,959	0.25	1,745,762,580	87.10%	1,103,389
21	Call general meetings on 14 days' notice*	1,657,330,730	94.88	89,418,003	5.12	1,746,748,733	87.15%	117,236

*Special Resolution

NOTES:

1.   All resolutions were passed.

2.   Votes "For" and "Against" are expressed as a percentage of votes received.

3.   A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

4.   Total number of shares in issue at close of business on 5 May 2021 was 2,004,347,138 shares; 87.15% of voting capital was instructed.

5.   Computershare acted as scrutineer of the poll on all resolutions.

In accordance with Listing Rule 9.6.2, copies of the resolutions that do not constitute ordinary business that were passed at the Meeting will be submitted to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com

Enquiries

Analysts and Investors

Kate Postans, Vice President Investor Relations, ConvaTec    +44 (0)7826 447 807

ir@convatec.com

Media

Buchanan: Charles Ryland / Chris Lane                                    +44 (0)207 466 5000                                                                                                        

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

# # #

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGUBSORAOUVRAR